TIME TO BUY!!!!!!!!!
BUYINS.NET: CTIC, Has been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days
Thursday May 22, 2008 09:35:54 EDT
May 22, 2008 (M2 PRESSWIRE via COMTEX News Network) --
Cell Therapeutics Inc. (NASDAQ:CTIC) markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin's lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington. With 94.61 million shares outstanding and 1.12 million shares declared short as of April 2008, the failure to deliver in shares of CTIC has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 116,714 shares of CTIC that were failing-to-deliver as of September 28, 2007.
Cell Therapeutics Inc. (NASDAQ:CTIC) markets lymphoma drug, Zevalin, in the United States. Zevalin is an FDA-approved radioimmunotherapeutic for treating lymphoma. The company also develops, acquires, and commercializes novel treatments for cancer. In addition, Cell Therapeutics develops XYOTAX for the treatment of non-small cell lung cancer and ovarian cancer; Pixantrone, a novel compound in the class of drugs known as anthracyclines, for non-Hodgkin's lymphoma; and Brostallicin, which is in first-line Phase II study for the treatment of sarcoma. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd. and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington. With 94.61 million shares outstanding and 1.12 million shares declared short as of April 2008, the failure to deliver in shares of CTIC has not been resolved and a buy-in is imminent. According to quarterly data provided by the SEC, there were still 116,714 shares of CTIC that were failing-to-deliver as of September 28, 2007. |
